Carregant...
Inflammatory bowel disease: towards a personalized medicine
The management of inflammatory bowel disease (IBD) has been transformed over the last two decades by the arrival of tumor necrosis factor (TNF) antagonist agents. Recently, alternative drugs have been approved, directed at leukocyte-trafficking molecules (vedolizumab) or other inflammatory cytokines...
Guardat en:
| Publicat a: | Therap Adv Gastroenterol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5784543/ https://ncbi.nlm.nih.gov/pubmed/29383027 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X17745029 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|